Published in Cancer Lett on November 12, 2008
Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene (2010) 1.62
The FoxO3/type 2 deiodinase pathway is required for normal mouse myogenesis and muscle regeneration. J Clin Invest (2010) 1.35
Muscling in: Uncovering the origins of rhabdomyosarcoma. Nat Med (2010) 1.31
Rhabdomyosarcoma in adolescent and young adult patients: current perspectives. Adolesc Health Med Ther (2014) 1.28
CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS One (2011) 1.22
Modeling sarcomagenesis using multipotent mesenchymal stem cells. Cell Res (2011) 1.09
JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene (2013) 1.05
Lineage of origin in rhabdomyosarcoma informs pharmacological response. Genes Dev (2014) 1.00
Differential regulation of the p73 cistrome by mammalian target of rapamycin reveals transcriptional programs of mesenchymal differentiation and tumorigenesis. Proc Natl Acad Sci U S A (2011) 0.97
Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2. Oncogene (2011) 0.96
CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV. Pediatr Blood Cancer (2012) 0.90
Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications. BMC Med (2011) 0.89
MiR-214 and N-ras regulatory loop suppresses rhabdomyosarcoma cell growth and xenograft tumorigenesis. Oncotarget (2014) 0.88
The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation. Cell Death Dis (2013) 0.86
Mouse models for cancer stem cell research. Toxicol Pathol (2009) 0.86
AKT and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell. Cell Cycle (2012) 0.86
Rhabdomyosarcoma: Advances in Molecular and Cellular Biology. Sarcoma (2015) 0.85
Rhabdomyosarcomas: an overview on the experimental animal models. J Cell Mol Med (2012) 0.84
Shared cell surface marker expression in mesenchymal stem cells and adult sarcomas. Stem Cells Transl Med (2012) 0.83
CIITA is silenced by epigenetic mechanisms that prevent the recruitment of transactivating factors in rhabdomyosarcoma cells. Int J Cancer (2012) 0.83
High IGFBP2 expression correlates with tumor severity in pediatric rhabdomyosarcoma. Am J Pathol (2011) 0.82
Fusion transcriptome profiling provides insights into alveolar rhabdomyosarcoma. Proc Natl Acad Sci U S A (2016) 0.82
Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma. Mol Cancer Ther (2013) 0.82
Induction of a regenerative microenvironment in skeletal muscle is sufficient to induce embryonal rhabdomyosarcoma in p53-deficient mice. J Pathol (2011) 0.82
Phosphocaveolin-1 enforces tumor growth and chemoresistance in rhabdomyosarcoma. PLoS One (2014) 0.81
An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. BMC Cancer (2014) 0.81
RasGRF1 regulates proliferation and metastatic behavior of human alveolar rhabdomyosarcomas. Int J Oncol (2012) 0.81
MicroRNAs in soft tissue sarcomas: overview of the accumulating evidence and importance as novel biomarkers. Biomed Res Int (2014) 0.79
Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression. Oncotarget (2015) 0.78
ARTEMIS stabilizes the genome and modulates proliferative responses in multipotent mesenchymal cells. BMC Biol (2010) 0.78
The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes with normal FOXO activity and the TGF-β pathway. PLoS One (2015) 0.77
Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcoma. Lab Invest (2015) 0.77
Primary pleomorphic rhabdomyosarcoma of the adrenal gland in an adult: A case report. Oncol Lett (2013) 0.75
The role of mesenchymal stem/progenitor cells in sarcoma: update and dispute. Stem Cell Investig (2014) 0.75
Fusion RNA profiling provides hints on cell of origin of mysterious tumor. Mol Cell Oncol (2016) 0.75
Hedgehog/Patched-associated rhabdomyosarcoma formation from delta1-expressing mesodermal cells. Oncogene (2015) 0.75
Does it make sense to target one tumor cell chemotactic factor or its receptor when several chemotactic axes are involved in metastasis of the same cancer? Clin Transl Med (2016) 0.75
Orbito-ethmoidal rhabdomyosarcoma in an adult patient: a case report and review of the literature. Case Rep Oncol (2014) 0.75
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science (2003) 7.86
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55
An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet (2003) 5.82
Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 5.62
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20
Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol (2006) 5.10
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med (2004) 5.01
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature (2005) 4.97
miR-19 is a key oncogenic component of mir-17-92. Genes Dev (2009) 4.95
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68
Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature (2004) 4.41
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest (2008) 4.13
Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med (2008) 3.98
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature (2005) 3.75
High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A (2004) 3.75
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res (2002) 3.72
Identification of a tumour suppressor network opposing nuclear Akt function. Nature (2006) 3.68
Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science (2003) 3.18
Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst (2004) 3.17
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature (2010) 3.09
PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature (2006) 3.01
Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev (2009) 2.99
p63 expression profiles in human normal and tumor tissues. Clin Cancer Res (2002) 2.68
Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest (2006) 2.68
PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 2.66
DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev (2008) 2.60
Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet (2007) 2.54
Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol (2003) 2.36
Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci U S A (2007) 2.36
Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res (2003) 2.34
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet (2013) 2.29
Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res (2002) 2.19
Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. J Clin Oncol (2003) 2.18
Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell (2012) 2.18
The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med (2007) 2.12
Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev (2005) 1.99
Integrative genome comparison of primary and metastatic melanomas. PLoS One (2010) 1.97
Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol (2003) 1.94
Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res (2007) 1.94
The TLX1 oncogene drives aneuploidy in T cell transformation. Nat Med (2010) 1.93
Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol (2010) 1.89
Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J Clin Oncol (2008) 1.89
Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol (2002) 1.88
Targeting nonclassical oncogenes for therapy in T-ALL. Cancer Cell (2012) 1.86
Cyfip1 is a putative invasion suppressor in epithelial cancers. Cell (2009) 1.77
Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell (2011) 1.74
The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. Immunity (2002) 1.70
Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest (2007) 1.66
Role of the chromobox protein CBX7 in lymphomagenesis. Proc Natl Acad Sci U S A (2007) 1.65
Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol (2002) 1.62
MDM2 and prognosis. Mol Cancer Res (2004) 1.62
Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev (2008) 1.61
Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer (2006) 1.60
Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res (2006) 1.60
Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res (2008) 1.60
Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest (2007) 1.59
ETS rearrangements and prostate cancer initiation. Nature (2009) 1.58
Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res (2005) 1.55
Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol (2003) 1.55
MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century. Expert Rev Anticancer Ther (2009) 1.54
Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome. Am J Pathol (2003) 1.49
Bone marrow stromal cells as replacement cells for Parkinson's disease: generation of an anatomical but not functional neuronal phenotype. Transl Res (2010) 1.48
Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci Signal (2009) 1.47
Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res (2002) 1.44
A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol (2008) 1.43
Gene expression profiling in single cells within tissue. Nat Methods (2005) 1.43
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res (2009) 1.43
PU.1 and pRB interact and cooperate to repress GATA-1 and block erythroid differentiation. Mol Cell Biol (2003) 1.42
Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res (2009) 1.41
Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol (2011) 1.39
p27 as a target for cancer therapeutics. Cancer Cell (2003) 1.38
p73alpha regulation by Chk1 in response to DNA damage. Mol Cell Biol (2003) 1.36
p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. Clin Cancer Res (2003) 1.35
miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol (2012) 1.34
Bax and Bak do not exhibit functional redundancy in mediating radiation-induced endothelial apoptosis in the intestinal mucosa. Int J Radiat Oncol Biol Phys (2008) 1.34
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res (2005) 1.31
The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147. Am J Pathol (2002) 1.30
Chk2 suppresses the oncogenic potential of DNA replication-associated DNA damage. Mol Cell (2008) 1.30
Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation. Nat Genet (2004) 1.29
Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. Clin Cancer Res (2002) 1.29
Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis. Hum Pathol (2003) 1.27
Role of Dok-1 and Dok-2 in leukemia suppression. J Exp Med (2004) 1.23
Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas. Am J Pathol (2002) 1.22
Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res (Phila) (2009) 1.22
Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. Clin Cancer Res (2003) 1.19
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res (2002) 1.19
Profiling bladder cancer using targeted antibody arrays. Am J Pathol (2006) 1.17
Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res (2003) 1.17
Translocation renal cell carcinomas in adults: a single-institution experience. Am J Surg Pathol (2012) 1.17
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res (2002) 1.16
PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. J Clin Invest (2012) 1.16